Alexis A, de Bruin-Weller M, Weidinger S, Soong W, Barbarot S, Ionita I, Zhang F, Valdez H, Clibborn C, Yin N (2022) Rapidity of improvement in signs/symptoms of moderate-to-severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study. Dermatol Ther (Heidelb) 12:771–785

Article  PubMed  Google Scholar 

Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M (2022) Efficacy and safety of Ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase ii study. Gastroenterology 163:1555–1568

Article  CAS  PubMed  Google Scholar 

Chopra R, Silverberg JI (2018) Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol 36:606–615

Article  PubMed  Google Scholar 

Clebak KT, Helm L, Uppal P, Davis CR, Helm MF (2023) Atopic dermatitis. Prim Care 50:191–203

Article  PubMed  Google Scholar 

Frazier W, Bhardwaj N (2020) Atopic dermatitis: diagnosis and treatment. Am Fam Physician 101:590–598

PubMed  Google Scholar 

Gatmaitan JG, Lee JH (2023) Challenges and future trends in atopic dermatitis. Int J Mol Sci 24(14):11380

Article  Google Scholar 

Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB (2021) Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis 12:20406223211002979

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gori N, Ippoliti E, Peris K, Chiricozzi A (2023) Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther 23:575–577

Article  PubMed  Google Scholar 

Guttman-Yassky E, Irvine AD, Brunner PM, Kim BS, Boguniewicz M, Parmentier J, Platt AM, Kabashima K (2023) The role of Janus kinase signaling in the pathology of atopic dermatitis. J Allergy Clin Immunol 152:1394–1404

Article  CAS  PubMed  Google Scholar 

Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N (2023a) Effectiveness and safety of Upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol 16:3201–3212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hagino T, Saeki H, Fujimoto E, Kanda N (2023b) Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol 50:869–879

Article  CAS  PubMed  Google Scholar 

Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL (2022) The eczema area and severity index-a practical guide. Dermatitis 33:187–192

Article  PubMed  PubMed Central  Google Scholar 

Heidari S, Babor TF, De Castro P, Tort S, Curno M (2016) Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 1:2

Article  PubMed  PubMed Central  Google Scholar 

Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS, Williams HC, Katoh N, Howells L, Schmitt J, Deckert S, Seshadri R, Simpson EL (2024) Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement. JAMA Dermatol 160:878–886and Harmonising Outcome Measures for Eczema i

Jaros J, Hendricks AJ, Shi VY, Lio PA (2020) A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis 31:169–177

Article  PubMed  Google Scholar 

Kellogg C, Smogorzewski J (2023) Update on atopic dermatitis. Adv Pediatr 70:157–170

Article  PubMed  Google Scholar 

Lio PA, Wollenberg A, Thyssen JP, Pierce EJ, Rueda MJ, DeLozier AM, Ross Terres JA, Anderson P, Milligan G, Piercy J, Silverberg JI, Paul C (2020) Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol 19:943–948

Article  PubMed  Google Scholar 

Maarouf M, Saberian C, Lio PA, Shi VY (2018) Head-and-neck dermatitis: diagnostic difficulties and management pearls. Pediatr Dermatol 35:748–753

Article  PubMed  Google Scholar 

Puerta Durango K, Chiesa Fuxench ZC (2024) Global burden of atopic dermatitis: examining disease prevalence across pediatric and adult populations world-wide. Dermatol Clin 42:519–525

Article  CAS  PubMed  Google Scholar 

Shih PY, Li CJ, Yong SB (2023) Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment. Int Immunopharmacol 124:111029

Article  CAS  PubMed  Google Scholar 

Shin YH, Hwang J, Kwon R, Lee SW, Kim MS, Collaborators GBDAD, Shin JI, Yon DK (2023) Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the global burden of disease study 2019. Allergy 78:2232–2254

Article  CAS  PubMed  Google Scholar 

Siegfried EC, Simpson EL, Cork MJ, Arkwright PD, Wine Lee L, Chen Z, Prescilla R, Bansal A, Levit NA, Rodriguez Marco A (2023) Dupilumab treatment leads to rapid and consistent improvement of atopic dermatitis in all anatomical regions in patients aged 6 months to 5 years. Dermatol Ther (Heidelb) 13:1987–2000

Article  PubMed  Google Scholar 

Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL, Gelfand JM (2019) Distribution of atopic dermatitis lesions in united states adults. J Eur Acad Dermatol Venereol 33:1341–1348

Article  CAS  PubMed  Google Scholar 

Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A (2025) Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the heads up study. Dermatology 241:10–18

CAS  PubMed  Google Scholar 

Wallace DV (2022) Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc 43:474–493

Article  CAS  PubMed  Google Scholar 

Wan H, Jia H, Xia T, Zhang D (2022) Comparative efficacy and safety of abrocitinib, baricitinib, and Upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther 35:e15636

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei W, Anderson P, Gadkari A, Blackburn S, Moon R, Piercy J, Shinde S, Gomez J, Ghorayeb E (2018) Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol 45:150–157

Article  CAS  PubMed  Google Scholar 

Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S (2023) Atopic dermatitis in children and adults-diagnosis and treatment. Dtsch Arztebl Int 120:224–234

PubMed  PubMed Central  Google Scholar 

Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB, Ko HC, Kim YH (2024) The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 38:52–61

Article  CAS  PubMed  Google Scholar 

Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, Goh AH, Liu R, Zhang Z, Zhang J (2021) Efficacy and safety of SHR0302, a highly selective Janus kinase 1 Inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial. Am J Clin Dermatol 22:877–889

Article  PubMed  PubMed Central  Google Scholar 

Zhao Y, Gooderham M, Yang B, Wu J, Wu L, Loo WJ, Toth D, Sauder M, Li J, Chen A, Tao X, Lu J, Song Z, Han J, Li H, Li Y, Xu L, Zhang J (2025) Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial. JAMA Dermatol 161:688–697

Article  PubMed  Google Scholar 

Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J (2023) A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of Ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol 89:911–919

Article  CAS  PubMed  Google Scholar